Skip to main content
Download PDF
Download ePub

Imaging the inflammatory phenotype in migraine

The Journal of Headache and Pain volume 23, Article number: 60 (2022) Cite this article

Abstract

Several preclinical and clinical lines of evidence suggest a role of neuroinflammation in migraine. Neuroimaging offers the possibility to investigate and localize neuroinflammation in vivo in patients with migraine, and to characterize specific inflammatory constituents, such as vascular permeability, and macrophage or microglia activity. Despite all imaging data accumulated on neuroinflammation across the past three decades, an overview of the imaging evidence of neuroinflammation in migraine is still missing.

We conducted a systematic review in the Pubmed and Embase databases to evaluate existing imaging data on inflammation in migraine, and to identify gaps in the literature. We included 20 studies investigating migraine without aura (N = 4), migraine with aura (N = 8), both migraine with and without aura (N = 3), or hemiplegic migraine (N = 5).

In migraine without aura, macrophage activation was not evident. In migraine with aura, imaging evidence suggested microglial and parameningeal inflammatory activity. Increased vascular permeability was mostly found in hemiplegic migraine, and was atypical in migraine with and without aura. Based on the weight of existing and emerging data, we show that most studies have concentrated on demonstrating increased vascular permeability as a marker of neuroinflammation, with tools that may not have been optimal. In the future, novel, more sensitive techniques, as well as imaging tracers delineating specific inflammatory pathways may further bridge the gap between preclinical and clinical findings.

Peer Review reports

Introduction

The hallmark of a migraine attack is severe headache accompanied by photophobia, phonophobia, and/or nausea [1], symptoms that are shared by other conditions characterized by meningeal inflammation. In animal models of migraine, neurogenic inflammation develops within the meninges and is mediated in part, by the release of vasoactive neuropeptides such as calcitonin gene-related peptide (CGRP), a molecule that plays a central role in migraine pathophysiology [2], and by cortical spreading depression, the mechanism strongly hypothesized to underlie aura [3]. This response is characterized by plasma extravasation, mast cell degranulation and possibly microglia/macrophage activation [3,4,5,6,7,8]. However, even though meningeal inflammation has not been consistently detected in clinical studies, more recently, different neuroimaging studies have supported the presence of an inflammatory signal in migraine patients. These have allowed in vivo visualization of inflammatory markers in human brain and surrounding tissues. Modalities and techniques include magnetic resonance imaging (MRI) to investigate macrophage-mediated inflammation [9] and extravasation [10, 11], single-photon emission computed tomography (SPECT) to evaluate extravasation [12], and positron emission tomography (PET) to assess activation of microglia and other inflammatory cell types [13, 14].

This article provides a systematic review of human neuroimaging studies focusing on inflammatory markers and their changes in patients with migraine. It critically appraises the weight of existing and emerging data, and evaluates the limitations of current methods used to study neuroinflammation. Finally, it considers how novel approaches, including those looking at inflammatory changes in the cortex and meninges, could play an important role in elucidating the involvement of neuroinflammation in migraine attacks, and potentially developing biomarkers for migraine.

Methods

A systematic review was conducted. Articles were identified through the PubMed and Embase databases using the search algorithm: Migraine AND (Inflammation OR macrophages OR microglia OR permeability OR edema) AND (MRI OR Gadolinium OR PET OR Positron Emission Tomography OR SPECT OR Single Photon Emission Computed Tomography). These search terms were decided on since they are imaging techniques that allow visualizing inflammatory changes in the CNS. Databases were searched from inception until 22nd of February 2022. In addition, articles were identified through references in the studies found by the search algorithms and by expert consultation. Two investigators (R.H.C. and C.G.) screened articles and extracted data.

Inclusion criteria were: imaging studies, clinical trials, case reports, or case series using imaging techniques considered sensitive to inflammatory changes (MRI with contrast agents, PET or SPECT techniques). Furthermore, only studies with migraine patients (including patients with debut of migraine or familial hemiplegic migraine) were included.

Exclusion criteria were: non-original articles, reviews, non-human studies, non-imaging techniques, non-migraine conditions, or studies providing no assessment of inflammatory changes. Studies examining e.g. cytotoxic edema without tracers were not included due to the limited specificity of this finding to inflammation.

Results

We identified 169 unique records based on database search and five records from other sources. Exclusion of 135 records was based on abstract reading. Nineteen full-text articles were assessed and excluded as they did not include imaging parameters assessing inflammatory changes (either tracers examining inflammatory cell types or contrast agents examining extravasation). Twenty studies were included in qualitative analysis Fig. 1.

Fig. 1
figure 1

Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) workflow chart of identified, excluded and included articles

Full size image

Of the 20 included studies, 4 investigated migraine without aura, 8 migraine with aura, 3 both migraine with and without aura, and 5 hemiplegic migraine. Fifteen studies used MRI contrast agents to examine inflammation, three used PET tracers, and 2 used SPECT tracers. For an overview of results from individual studies, see Tables 1, 2, and 3. In the tables, studies which included an evaluation of possibly meningeal enhancement or uptake are separated from studies which did not. Perfusion data are reported where this supports interpretation of the results. In the following, we present results from individual structured studies which carried out statistical analysis, and overviews of results from case reports or studies without statistical analysis within their respective sections.

Table 1 MRI contrast agent studies in migraine patients with (MA) and without aura (MO) to detect an inflammatory phenotype
Full size table
Table 2 Imaging studies in familial and sporadic hemiplegic migraine (FHM/SHM) to detect an inflammatory phenotype
Full size table
Table 3 PET/SPECT studies in migraine patients with (MA) and without (MO) aura to detect an inflammatory phenotype
Full size table

MRI with contrast agents

A key feature of inflammation is vascular permeability. Because gadolinium-based MRI contrast agents extravasate through leaky vessels, gadolinium enhancement and transfer rates provide estimates of vascular permeability (Table 4).

Table 4 Assumptions of gadolinium-contrast MRI
Full size table

Migraine without aura

Three structured studies, one case report, and one uncompleted study investigated the presence of increased vascular permeability (disruption of the blood-brain barrier (BBB)) in migraine without aura (MO) (Table 1). All but one MRI study in patients with MO used gadolinium or derivatives thereof (see Table 1). Only one study analyzed BBB permeability in the interictal period in 14 patients with MO and 21 patients with migraine with aura (MA) [16]. All other studies were performed in the ictal period.

Amin et al. examined 19 patients with MO during and outside of attacks using gadolinium contrast [11]. Patients were scanned a mean of 6.5 h after attack onset. The study found no change in BBB permeability for gadolinium between the ictal and interictal scan for any of the regions of interest (ROIs) (including hemispheres, anterior, middle, or posterior cerebral areas, brain stem areas, or posterior pons). For patients with unilateral head-pain during the attack, there were no differences between the pain side compared to the non-pain side for any of the ROIs.

Khan et al. examined macrophage activation in patients with MO using the MRI contrast agent ultra-small superparamagnetic iron oxide (USPIO), which is engulfed by activated macrophages and extravasates when the BBB is disrupted [9] (Table 1). Twenty-eight patients with MO ingested cilostazol and developed migraine attacks with unilateral headache, 12 of which were treated with sumatriptan subcutaneously. All 28 participants then received infusion with USPIO and were scanned 27 hours after infusion of USPIO. The 27 hour time point was selected since delayed USPIO uptake is thought to reflect cellular uptake, while USPIO also acted as a blood pool agent initially [31, 32]. The study found no difference in USPIO uptake for the pain side compared to the non-pain side in brain parenchyma, the middle cerebral artery, cavernous part of the internal carotid artery, or upon visual inspection of the dura mater. However, in post-hoc analysis, the transverse relaxation rate (ΔR2*) was increased bilaterally in the anterior cerebral artery territory for the group without sumatriptan treatment, and ΔR2* was higher on the pain-side for the untreated patients. Tissue uptake of USPIO increases ΔR2* [33].

One cases series comprising seven patients with migraine (5 MO, 2 MA) investigated intradural intracranial vessel wall enhancement with gadolinium, but found no enhancement during or outside of attacks in 6 patients. The remaining patient had focal vertebral artery enhancement, but this persisted interictally and was likely attributable to an atherosclerotic plaque [15], which gadolinium contrast enhances [34]. An unclear number of the patients had consumed anti-inflammatory analgesics or triptans.

Migraine with aura

Three structured studies and five case reports have examined the presence of increased vascular permeability in MA (Table 1).

Three case reports showed meningeal enhancement in gadolinium-contrasted MR that evocated BBB leakage, during prolonged or atypical auras in MA [18,19,20]. One other case report found holohemispheric enhancement [17], and another sulcal hyperintensity on gadolinium enhanced FLAIR [21].

Hougaard et al. examined BBB permeability for gadolinium in 21 patients with MA after aura compared to attack-free days [10]. The mean time from aura onset until scan was 7.6 h. The study found no differences in BBB permeability after aura compared to attack free days, and no difference between hemispheres. There was no correlation between BBB permeability and the time from symptom onset until scan. No healthy controls (HCs) were included for comparison. Kim et al. compared BBB permeability in 35 interictal patients with migraine (21 patients with MA, and 14 with MO) with 21 HCs using gadolinium contrast [16]. The study found no differences in BBB permeability between the groups.

Hemiplegic migraine

In hemiplegic migraine, one case series reported eight attacks in two patients of the same family. Six of the eight attacks were analyzed with contrast agent and only one attack showed cortical enhancement in the symptomatic brain area [24].

Four case reports have observed gadolinium-contrast MR enhancement of the meninges which could be accompanied by cortical edema [22, 23, 25, 26]. These findings revealed permeability changes, that repeatedly occurred in the gyri, but were also present in the dura matter (Table 2) [22].

PET/SPECT

In PET and SPECT technique, radioactive tracers are used to locate and quantify specific molecules to determine their possible pathophysiological involvement (Table 5).

Table 5 Assumptions of PET/SPECT imaging
Full size table

Migraine without aura

One case report and preliminary results from an incomplete study used technetium-99m labeled human serum albumin (99Tc-HSA) to estimate extravasation in patients with MO (Table 3). For one patient, there was SPECT enhancement along the right frontal convexity 3 hours after tracer infusion in an attack of migraine without aura [12, 27]. This corresponded to the location of the patient’s headache [12].

Another SPECT study examined parasellar uptake of gallium-67 citrate in migraine without aura, in the context of a study on cluster headache. The study included 7 patients with MO and found parasellar hyperactivity in 56% of patients with migraine. However, parasellar hyperactivity was also observed for cluster headache patients and no statistical comparison was made [29].

Schankin et al. examined BBB permeability with 11C-dihydroergotamine (11C-DHE) PET in glyceryl trinitrate (GTN)-induced migraine attacks without aura [28]. The study included 6 patients with migraine (4 with MO patients, 2 with MA) and 6 healthy controls. The study found no differences in uptake of 11C-DHE in patients with migraine during attacks compared to outside of attacks, or in healthy controls before GTN infusion compared to after GTN infusion. None of the healthy controls developed headache after GTN infusion in this study.

Migraine with aura

The PET tracer 11C-PBR28 targets the membrane protein translocate protein (TSPO), which upregulates on multiple cell types, including microglia, macrophages, and astrocytes during inflammation [35, 36].

In patients with MA, a PET-MRI study used the tracer to detect inflammatory upregulation in the cerebrum of patients with MA interictally [13]. Thirteen patients with MA were compared to 16 healthy controls. All patients with MA had at least one aura attack within 15 days preceding the scan. Compared to healthy controls, patients with MA had widespread increased tracer uptake across several cortical sites, including occipital striate and extrastriate visual cortex, somatosensory cortex, insula, thalamus, and in the spinal trigeminal nucleus (Table 3). This was correlated with the number of migraine attacks per month in several cortical and subcortical areas including frontoinsular cortex, primary/secondary somatosensory cortices, and basal ganglia.

Using the same PET tracer, the group also examined uptake in parameningeal tissues (the dura mater, brain, and bone barrow) [14]. The study included 11 patients with frequent visual MA, who were scanned within 18 days after their last migraine attack with or without aura, and who had at least one aura attack within the preceding four weeks. Some of these patients also experienced MO. In addition, the study included control groups of 11 healthy controls and 11 patients with chronic lower-back pain. The study found increased uptake in the parameningeal tissue overlying the occipital cortex, when comparing to healthy controls and patients with chronic lower-back pain. In the occipital parameningeal tissue, the uptake was correlated with the total number of visual auras.

Discussion

Our discussion is intended to examine the overlapping and complementary preclinical and clinical evidence to support human imaging findings in patients with MO and patients with MA. The strength and weakness of the data will be considered. When appropriate, recommendations will be made for how to proceed to advance the translational evidence from animal to human.

Migraine without aura

Evidence of macrophage involvement

Preclinical findings suggest that macrophages participate in a delayed inflammatory response that may take place in the meninges in migraine [7, 37]. This was investigated using the nitric oxide-donor glyceryl trinitrate (GTN), which induced migraine attacks in 70-80% of patients with migraine when given intravenously [38]. When given to rodents, GTN activated dural macrophages along the middle meningeal artery to express proinflammatory and nociceptive inducible nitric oxide synthase (iNOS), interleukin-1β (IL-1β), and interleukin-6 (IL-6) [7]. The macrophages activated with a delay of 2 hours, comparable to the timing of migraine headache induced after GTN infusion [7, 39]. As histological examination is not feasible in humans, clinical studies examined monocytes in blood taken from the jugular vein during spontaneous migraine attacks instead, finding increased iNOS expression and higher levels of IL-1β and IL-6 [40, 41].

To localize a site for this monocyte/macrophage activation in patients with MO, an imaging study subsequently used the MRI contrast agent USPIO, which is engulfed by activated macrophages [9]. The study looked for lateralized differences in patients who experienced unilateral migraine headache after cilostazol ingestion. However, the study found no differences in side-to-side signal intensity in the middle cerebral artery (MCA) or cavernous segment of the internal carotid artery (ICAcavernous), for vascular territories supplied by the anterior cerebral artery (ACA), MCA, or posterior cerebral artery (PCA), for the pons or thalamus, or upon visual inspection of the brain parenchyma or dura mater. While patients who did not receive sumatriptan treatment for the attack had a higher uptake than patients who received treatment, this was investigated as a post-hoc analysis. It is possible that sumatriptan treatment could have attenuated macrophage activity in the primary analysis.

Of note, since the study did not compare the uptake of USPIO between patients with MO and HC, nor between during and outside an attack, no inferences can be made about changes in macrophage activity during attacks. To analyze attack-specific macrophage activity, uptake could be compared between patients who did and did not experience a migraine attack after receiving a migraine provoking substance, or between spontaneous migraine attacks and the interictal state. Furthermore, the timing of the study with scans 27 hours after transfer infusion, may not have permitted detection of transient changes in the beginning of the attack. Finally, statistical testing was not possible for the dura mater or the middle meningeal artery, where macrophage activation was initially implicated in preclinical studies.

Evidence of vascular permeability

Most imaging studies in MO have examined vascular permeability that could be the consequence of inflammation. In rats, antidromic trigeminal activation leads to release from C and Aδ fibers of inflammatory neuropeptides which induces dural plasma protein extravasation [42]. Neuropeptides such as substance P directly induces extravasation [42, 43], while others, e.g. CGRP, do so indirectly [44,45,46] by stimulating mast cell degranulation and histamine release [47, 48]. GTN infusion in rats caused a similar, but delayed plasma protein extravasation, suggesting an identical response could occur in patients with migraine [7]. Vascular permeability and BBB function could also deteriorate due to the activity of matrix metalloproteinases (MMPs), extracellular proteolytic enzymes that regulate inflammation and disrupt the BBB [49, 50]. While early findings suggested MMPs to be dysregulated in patients with MO [51,52,53], findings of increased MMP-9 levels during MO attacks [53, 54] could not be replicated in a study measuring in blood from the external jugular vein [55].

Neuroimaging offers the opportunity to visualize this extravasation in patients with MO. Two initial clinical cases reported an increased uptake in meningeal 99Tc-HSA ipsilateral to the patient’s migraine headache. The uptake was increased three hours after tracer injection, and not on early acquisition [12, 27], which suggests that the uptake corresponded to extravasation of the tracer and not only hyperemia [12]. However, how vascular changes evolve over time during migraine has not specifically been evaluated. Another study measured high parasellar uptake of gallium [29], whose uptake is enhanced by increased blood flow and vascular membrane permeability [56]. However, the uptake was also high in cluster headache, and the region is not relevant for migraine pathophysiology. To verify whether plasma protein extravasated during migraine attacks, structured human imaging studies subsequently used the transfer rate of gadolinium or hydrophilic molecules of a similar size to investigate and quantify BBB permeability [11, 16, 28]. However, scans of 25 MO patients during attacks (19 spontaneous, 6 GTN-provoked) found no difference in BBB permeability for gadolinium or the migraine treatment dihydroergotamine compared to the interictal state [11, 28]. Another study found no difference between patients with MO interictally and healthy controls, but substantial variation in the gadolinium transfer rate limited interpretation of this finding [16].

Importantly, the structured studies lacked the statistical power to detect minor differences in blood-to-brain leakage of gadolinium [11, 16], which may not be sufficiently sensitive to detect minor changes in vascular permeability. Furthermore, the structured studies could not directly examine the meninges, since the resolution of standard MRI is too low to explore the meninges specifically. However, a recent case series examined intradural vascular gadolinium uptake using vessel wall MRI during and outside attacks of migraine (mixed MO and MA). The time from headache onset until scan was not reported but was <24 hours for all patients [15]. The study did not find vessel wall enhancement in intradural intracranial vessels, but all participants had consumed anti-inflammatory analgesics or triptans before their scan, and therefore one cannot exclude that they may have quenched an inflammatory signal. Finally, no statistical comparison was performed, and the case series did not include healthy controls.

Migraine with aura

Animal models of migraine with aura suggest a proinflammatory role of cortical spreading depression (CSD), the neural correlate of aura symptoms. In neurons, CSD activates a distinct inflammatory pathway by increasing Pannexin 1 megachannel opening and caspase-1 activation, subsequently resulting in neural high mobility group protein (HMGB1) release. This stimulates nuclear factor-κβ (NF-κβ) activation in astrocytes, inducing transcription of cytokines and proinflammatory enzymes and headache behavior in animal experiments [57].

Evidence of macrophage involvement

In rodents, manipulating the cortex with electrodes triggered CSD, which activated meningeal macrophages [58, 59]. In the dura, macrophage activation was delayed by 20 minutes, a time frame similar to the delay from aura onset until headache onset in the majority of patients with MA [60]. Macrophages may release cytokines such as IL-1β and tumor necrotizing factor-α (TNF-α) that are reported as elevated after CSD [61] and in patients with MA [62]. These could sensitize meningeal afferents directly (e.g. IL-1 [63] and TNF-α [64]) or indirectly by increasing CGRP release [65].

Though no imaging studies directly examined macrophage activation in patients with MA, one study reported increased uptake of the tracer 11C-PBR28 in patients with multiple attacks of migraine with visual aura within the parameningeal tissues (Table 3). TSPO is the peripheral benzodiazepine receptor and upregulates during inflammation in several cell types, including macrophages. Enhanced uptake was associated with the total number of visual auras in the preceding 4 weeks [14]. In these patients, averaging 8 attacks over the prior 30 days, enhanced tracer uptake persisted for at least 18 days after the last attack. It is unknown as yet whether this uptake occurs in migraine without aura [14].

Complementary to the above, a recent study using micro-computed tomography (μCT) demonstrated the existence of microvascular channels in human skull. These channels allow leucocytes derived from skull bone marrow to migrate towards the brain to reach the meninges [66], as demonstrated in chemical meningitis and stroke. To explain the enhanced 11C-PBR28 uptake in the bone marrow, it has been posited that inflammatory signal(s) generated in cortex following CSDs (e.g., cytokines and/or HMGB-1) are released and taken up by microvascular channels to reach the bone marrow. Within the bone marrow, these signals provoke the migration of myeloid cells towards the meninges overlying the occipital cortex, the source of CSD in visual auras. Indeed, the demonstration of enhanced tracer uptake in visual cortex overlying meninges, and adjacent bone marrow supports the above formulation after multiple migraine with aura attacks [14]. Whether the findings and formulation relate to the pathogenesis of recurrent and frequent migraine with aura attacks remain to be determined.

Evidence of microglia involvement

Animal models of migraine with aura suggest neuroinflammatory activation of microglia. As delineated above, cortical spreading depression initiates a complex cascade involving pannexin 1 channel opening with subsequent microglial activation. Like macrophages, activated microglia may release proinflammatory cytokines [67, 68] which can sensitize perivascular nociceptive afferents. In addition, activated microglia express TSPO [6, 69], which exhibited sustained upregulation in animals after CSD, when examined with a PET tracer [6].

Similar pro-inflammatory upregulation was replicated in patients with MA interictally with the TSPO tracer 11C-PBR28 [69], suggesting pro-inflammatory microglial activation or recruitment [70]. TSPO was upregulated in several regions previously implicated in MA, including occipital striate and extrastriate visual cortex, somatosensory cortex, insula, thalamus, and in the spinal trigeminal nucleus [13]. There was an association between frequent migraine attacks and uptake of the tracer in the human neuroimaging study, which may reflect a cumulative impact of multiple CSDs on microglial activation or number, sufficient to detect clinically. Similar cumulative effects of multiple CSDs have been observed preclinically [71].

Of note, 11C-PBR28 binds non-specifically to activated macrophages, monocytes, neutrophils, dendritic cells, mast cells, and adipocytes besides microglia [14]. Although this shortcoming limits the ability to dissect the contribution of individual cell types in the inflammatory process, it does have the advantage of detecting a composite of the inflammatory process in multiple cell types, thereby enhancing the overall signal intensity. The development of more cell type-specific ligand will add another dimension to these new and important findings.

Evidence of vascular permeability

In animal models of migraine, CSD induces extravasation of plasma proteins from dura mater vasculature, by activating trigeminal afferents [3, 57, 72]. In rats, trigeminal activation after CSD may activate and upregulate the BBB degrading enzyme MMP-9, which results in plasma protein leakage [49]. Though attacks in patients with MA have been associated with increased MMP-9 concentrations [53], it is uncertain whether MMP-9 levels differ between patients with MA interictally and healthy controls [51, 54].

In MA, a BBB breakdown has been visualized in a few clinical cases with contrast extravasation on MRI [17,18,19,20,21]. However, these were prolonged auras [17, 21] or atypical cases in which differential diagnoses such as hemiplegic migraine, cerebral amyloid angiopathy or transient headache and neurological deficits with cerebrospinal fluid lymphocytosis (HANDL) syndrome cannot be completely excluded [18,19,20]. In a structured study of typical cases of MA in 19 patients, Hougaard et al. found no increase in BBB permeability for gadolinium during the migraine headache [10]. However, comparisons to healthy controls were not made, and there was a lack of statistical power to detect minor permeability changes. In this study, patients were studied during hypoperfusion or hyperperfusion phases. Interestingly, in the case published by Rostein et al., the observed increase in BBB permeability observed was contemporaneous with ipsilateral hypoperfusion, which would suggest a BBB disruption unrelated to hyperemia [17]. To our knowledge, this is a unique observation.

Hemiplegic migraine

Hemiplegic migraines (HM) could be sporadic (SHM) or familial (FHM). Familial HM can be due to several genetic mutations, which all increase the susceptibility to CSD. In patients with HM, CSD could induce more pronounced extravasation of plasma proteins than in classical aura, since preclinical studies suggest multiple CSDs amplify plasma protein extravasation [71]. This corresponds to the severe neurological paresis characterizing the disorder.

One structured imaging study (N = 2) [24] and 4 case reports examined changes in vascular permeability in FHM, while one case report examined changes in vascular permeability in SHM (Table 2). Contrast agent extravasated in 5 out of 13 hemiplegic migraine attacks. These were always prolonged auras, and the extravasation of contrast agent was extensive, sometimes associated with cortical oedema, and was seen in a phase of hyperemia [22,23,24,25,26].

The increased vascular permeability reported in human neuroimaging studies of FHM [22,23,24] (Table 2) supports preclinical findings of leaky vessels after CSD [72]. However, there is a need for structured studies using sensitive methods to detect extravasation, to confirm these findings in a broader population of patients with FHM. Studying specific components of CNS inflammation, such as macrophage or microglial activation, as has been done in patients with MO and MA, would also be essential to determine if specific inflammatory pathways are involved in FHM.

Future perspectives

Most human imaging studies have focused on changes in vascular permeability to detect a key feature of inflammation in brain and surrounding tissues. In MA, neuroimaging studies have found neuroinflammatory activity in the cortex (possibly microglial in origin) and parameningeal tissues (possibly monocytic in nature). Imaging signs of neuroinflammation in MO have been less convincing. Major disruption of the BBB has not been observed consistently, although subtle or transient changes cannot be ruled out. The presence of a BBB breakdown is mainly seen in cases of atypical and prolonged auras as in hemiplegic migraine. In the classic forms of aura this observation is exceptional, and in MO it is uncertain. Furthermore, it is not clear whether the observed barrier breaks are due to hyperemia or inflammation or both. Only one observation showing extravasation at a hypoperfusion phase supports the second hypothesis [17]. It is possible that the common methods used lack the sensitivity to detect subtle disruptions of the BBB [10]. Future studies should apply more sensitive methods to detect extravasation, e.g. dynamic contrast-enhanced MRI (DCE-MRI) with longer acquisition times, or methods other than those based on gadolinium tracer, e.g. detecting molecular diffusion of intra- and extra-cellular water with T1 and T2 mapping.

Novel tracers targeting molecules upregulated during specific inflammatory processes, such as the leukocyte trafficking molecule urokinase plasminogen activated receptor, could then define components of an inflammatory response further. However, there are still many relevant targets in migraine for whom tracers have not been developed yet.

Other methodological considerations apply to the study of neuroinflammation in migraine in general. Timing of scans with regard to migraine phase may be essential to detect transient changes; serial scans during the migraine prodrome, headache, and resolution should be conducted to determine the time window of such transient changes. Importantly, temporal considerations may depend on the individual inflammatory event. For example, preclinical and clinical studies suggest extravasation is most likely to occur a few hours into migraine attacks, whereas microglial activation may not begin until a few days after CSD [6]. Furthermore, studies should be sufficiently powered to detect discrete inflammatory changes in macrophage activity or BBB permeability.

Meningeal and vascular inflammation is relatively unexamined. Preclinical studies suggest this location to be a prime candidate for inflammation in MO [7]. The dura lacks a BBB and has a composition and resident inflammatory cells distinct from those in the brain. Imaging data show that the middle meningeal artery (MMA) dilates specifically on the pain side in cilostazol-induced attacks [73]. However, several studies with MRI contrast agents did not report whether there was an overt dural enhancement or not, but this would probably have been mentioned if present. Future studies should explicitly report whether dural enhancement was observed or not. With future high-resolution imaging techniques, it may be possible to analyze the meninges separately. Neuroimaging studies should also continue to explore inflammatory changes in the cortex of patients with MA, particularly in relation to CSD.

Establishing the role of inflammatory pathways in migraine pathophysiology could help identify locations and targets for specific anti-migraine treatments and contrast the different migraine types. For example, the extent to which the BBB is altered or not in migraine is essential to determine the site of action of current and future migraine treatments. Neuroinflammatory imaging signals may also become possible future biomarkers for migraine. Therefore, it will be critical to determine whether microglial activation occurs in MO (especially whether the tracer 11C-PBR28 shows similarities in MO and MA), if macrophage activation occurs in MA, and if either occurs in FHM.

In summary, brain imaging circa 2022 provides an essential tool to understand the natural history of migraine and is a viable way to reconcile emerging preclinical and clinical data. It also holds great promise for discovering and interrogating key biological processes in human brain underlying this enigmatic neurovascular disorder. At this point, more studies are needed along with more specific and selective markers of cells and tissues as well as efforts to harmonize the protocols and newly acquired data sets between laboratories.

Acknowledgments

Dr. Gollion reports personal fees for consultancy from Teva. Dr. Amin has received honoraria and personal fees from Teva, Lundbeck, Novartis, Eli Lilly for lecturing or participating in advisory boards. Dr. Hadjikhani received grant support from the National Institute of Healthy, grant NIH-NCCAM 5P01AT009965-03. Dr. Ashina has received personal fees from AbbVie/Allergan, Amgen, Eli Lilly, Lundbeck, Novartis and Teva Pharmaceuticals, and is the principal investigator of ongoing clinical trials for AbbVie/Allergan, Amgen, and Lundbeck. He has received research grants from the Lundbeck Foundation, Novo Nordisk Foundation, and Novartis. He is associate editor of Brain, Cephalalgia, and The Journal of Headache and Pain. He is past President of the International Headache Society. Dr. Moskowitz and Dr. Christensen have no disclosures to report.

References

  1. IHS (2018) The International Classification of Headache Disorders, 3rd edition (beta version), Headache Classification Committee of the International Headache Society. Cephalalgia 38:629–808

    Google Scholar 

  2. Moskowitz MA (1993) Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 43:S16–S20

    CAS  PubMed  Google Scholar 

  3. Bolay H, Reuter U, Dunn AK et al (2002) Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 8:136–142

    Article  CAS  PubMed  Google Scholar 

  4. Pusic KM, Pusic AD, Kemme J, Kraig RP (2014) Spreading Depression Requires Microglia and is Decreased by their M2a Polarization from Environmental Enrichment. Glia 62:1176

    Article  PubMed  PubMed Central  Google Scholar 

  5. Magni G, Boccazzi M, Bodini A et al (2019) Basal astrocyte and microglia activation in the central nervous system of Familial Hemiplegic Migraine Type I mice. Cephalalgia 39:1809

    Article  PubMed  Google Scholar 

  6. Cui Y, Takashima T, Takashima-Hirano M et al (2009) 11C-PK11195 PET for the in vivo evaluation of neuroinflammation in the rat brain after cortical spreading depression. J. Nucl. Med. 50:1904–1911

    Article  CAS  PubMed  Google Scholar 

  7. Reuter U (2001) Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 124:2490–2502

    Article  CAS  PubMed  Google Scholar 

  8. Huang Z, Byun B, Matsubara T, Moskowitz MA (1993) Time-dependent blockade of neurogenic plasma extravasation in dura mater by 5-HT1B/D agonists and endopeptidase 24.11. Br J Pharmacol 108:331

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Khan S, Amin FM, Fliedner FP et al (2019) Investigating macrophage-mediated inflammation in migraine using ultrasmall superparamagnetic iron oxide-enhanced 3T magnetic resonance imaging. Cephalalgia 39:1407–1420

    Article  PubMed  Google Scholar 

  10. Hougaard A, Amin FM, Christensen CE et al (2017) Increased brainstem perfusion, but no blood-brain barrier disruption, during attacks of migraine with aura. Brain:1–10

  11. Amin FM, Hougaard A, Cramer SP et al (2017) Intact blood-brain barrier during spontaneous attacks of migraine without aura: a 3T DCE-MRI study. Eur J Neurol 24:1116–1124

    Article  CAS  PubMed  Google Scholar 

  12. Knotkova H, Pappagallo M (2007) Imaging intracranial plasma extravasation in a migraine patient: a case report. Pain Med 8:383–387

    Article  PubMed  Google Scholar 

  13. Albrecht DS, Mainero C, Ichijo E et al (2019) Imaging of neuroinflammation in migraine with aura: A [11C]PBR28 PET/MRI study. Neurology. https://doi.org/10.1212/WNL.0000000000007371-10.1212/WNL.000000000

  14. Hadjikhani N, Albrecht DS, Mainero C et al (2020) Extra-Axial Inflammatory Signal in Parameninges in Migraine with Visual Aura. Ann Neurol 87:939–949

    Article  PubMed  PubMed Central  Google Scholar 

  15. Merli E, Rustici A, Gramegna LL et al (2022) Vessel-wall MRI in primary headaches: The role of neurogenic inflammation. Headache J Head Face Pain 00:1–8

    Google Scholar 

  16. Kim YS, Kim M, Choi SH et al (2019) Altered Vascular Permeability in Migraine-associated Brain Regions: Evaluation with Dynamic Contrast- enhanced MRI. Radiology. https://doi.org/10.1148/radiol.2019182566

  17. Rotstein DL, Aviv RI, Murray BJ (2012) Migraine with aura associated with unilateral cortical increase in vascular permeability. Cephalalgia 32:1216–1219

    Article  CAS  PubMed  Google Scholar 

  18. Smith M, Cros D, Sheen V (2002) Hyperperfusion with vasogenic leakage by fMRI in migraine with prolonged aura. Neurology 58:1308–1310

    PubMed  Google Scholar 

  19. Lanfranconi S, Corti S, Bersano A et al (2009) Aphasic and visual aura with increased vasogenic leakage: an atypical migrainosus status. J Neurol Sci 285:227–229

    Article  PubMed  Google Scholar 

  20. Arnold G, Reuter U, Kinze S et al (1998) Migraine with aura shows gadolinium enhancement which is reversed following prophylactic treatment. Cephalalgia 18:644–646

    Article  CAS  PubMed  Google Scholar 

  21. Gómez-Choco M, Capurro S, Obach V (2008) Migraine with aura associated with reversible sulcal hyperintensity in FLAIR. Neurology 70:2416–2418

    Article  PubMed  Google Scholar 

  22. Dreier JP, Jurkat-Rott K, Petzold GGCG et al (2005) Opening of the blood-brain barrier preceding cortical edema in a severe attack of FHM type II. Neurology 64:2145–2147

    Article  CAS  PubMed  Google Scholar 

  23. Cha YH, Millett D, Kane M et al (2007) Adult-onset hemiplegic migraine with cortical enhancement and oedema. Cephalalgia 27:1166–1170

    Article  PubMed  Google Scholar 

  24. Iizuka T, Takahashi Y, Sato M et al (2012) Neurovascular changes in prolonged migraine aura in FHM with a novel ATP1A2 gene mutation. J Neurol Neurosurg Psychiatry 83:205–212

    Article  PubMed  Google Scholar 

  25. Iizuka T, Sakai F, Suzuki K et al (2006) Implication of augmented vasogenic leakage in the mechanism of persistent aura in sporadic hemiplegic migraine. Cephalalgia 26:332–335

    Article  CAS  PubMed  Google Scholar 

  26. Pellerin A, Marois C, Mezouar N et al (2019) Neuronal injuries evidenced by transient cortical magnetic resonance enhancement in hemiplegic migraine: A case report. Cephalalgia 39:323–325

    Article  PubMed  Google Scholar 

  27. Pappagallo M, Szabo Z, Esposito G, Lokesh A, Velez L (1999) Imaging neurogenic inflammation in patients with migraine headaches. Neurology 52:A274–A275

    Google Scholar 

  28. Schankin CJ, Maniyar FH, Seo Y et al (2016) Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11 C-dihydroergotamine during glyceryl trinitrate-induced migraine. https://doi.org/10.1093/aww112

  29. Sianard-Gainko J, Milet J, Ghuysen V, Schoenen J (1994) Increased parasellar activity on Gallium SPECT is not specific for active cluster headache. Cephalalgia 14:132

    Article  CAS  PubMed  Google Scholar 

  30. PubChem Identifier: CID 65430 URL: https://pubchem.ncbi.nlm.nih.gov/compound/Gallium-citrate-ga-67. Accessed 23 Oct 2020.

  31. Farrell BT, Hamilton BE, Dosa E, et al (2013) Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL. American Academy of Neurology

  32. Saleh A, Schroeter M, Jonkmanns C et al (2004) In vivo MRI of brain inflammation in human ischaemic stroke. Brain 127:1670–1677

    Article  PubMed  Google Scholar 

  33. Neuwelt EA, Várallyay CG, Manninger S et al (2007) The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous systemt malignancy: a pilot study. Neurosurgery 60:601–612

    Article  PubMed  Google Scholar 

  34. Wasserman BA, Smith WI, Trout HH et al (2002) Carotid Artery Atherosclerosis: In Vivo Morphologic Characterization with Gadolinium-enhanced Double-oblique MR Imaging—Initial Results1. 101148/radiol2232010659. 223:566–573

  35. Pannell M, Economopoulos V, Wilson TC et al (2020) Imaging of translocator protein upregulation is selective for pro-inflammatory polarized astrocytes and microglia. Glia 68:280–297

    Article  PubMed  Google Scholar 

  36. Nutma E, Gebro E, Marzin MC et al (2021) Activated microglia do not increase 18 kDa translocator protein (TSPO) expression in the multiple sclerosis brain. https://doi.org/10.1002/glia.24052

  37. Reuter U, Chiarugi A, Bolay H, Moskowitz MA (2002) Nuclear factor-κB as a molecular target for migraine therapy. Ann Neurol 51:507–516

    Article  CAS  PubMed  Google Scholar 

  38. Olesen J, Iversen HK, Thomsen LL (1993) Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 4:1027–1030

    Article  CAS  PubMed  Google Scholar 

  39. Thomsen LL, Kruuse C, Iversen HK, Olesen J (1994) A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1:73–80

    Article  CAS  PubMed  Google Scholar 

  40. Sarchielli P, Floridi A, Mancini ML et al (2006) NF-κ B activity and iNOS expression in monocytes from internal jugular blood of migraine without aura patients during attacks. © Blackwell Publ Ltd. Cephalalgia 26:1071–1079

    Article  CAS  PubMed  Google Scholar 

  41. Sarchielli P, Alberti A, Baldi A et al (2006) Proinflammatory Cytokines, Adhesion Molecules, and Lymphocyte Integrin Expression in the Internal Jugular Blood of Migraine Patients Without Aura Assessed Ictally. Headache J Head Face Pain 46:200–207

    Article  Google Scholar 

  42. Markowitz S, Saito K, Moskowitt MA et al (1987) Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 7:4129–4136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Lembeck F, Holzer P (1979) Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 310:175–183

    Article  CAS  PubMed  Google Scholar 

  44. Schwenger N, Dux M, De Col R et al (2006) Interaction of calcitonin gene-related peptide, nitric oxide and histamine release in neurogenic blood flow and afferent activation in the rat cranial dura mater. Cephalalgia 27:481–491

    Article  Google Scholar 

  45. Rozniecki JJ, Dimitriadou V, Lambracht-Hall M et al (1999) Morphological and functional demonstration of rat dura mater mast cell-neuron interactions in vitro and in vivo. Brain Res 849:1–15

    Article  CAS  PubMed  Google Scholar 

  46. Dimtriadou V, Buzzi MG, Moskowitz MA, Theoharides TC (1991) Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura mater mast cells. Neuroscience 44:97–112

    Article  Google Scholar 

  47. Dux E, Joó F (1982) Effects of Histamine on Brain Capillaries. Exp Brain Res 47:252–258

    Article  CAS  PubMed  Google Scholar 

  48. Sarker MH, Easton AS, Fraser PA (1998) Regulation of cerebral microvascular permeability by histamine in the anaesthetized rat. J Physiol 507:909

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Gursoy-Ozdemir Y, Lo EH, Moskowitz MA et al (2004) Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 113:1447–1455

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Gurney KJ, Estrada EY, Rosenberg GA (2006) Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 23:87–96

    Article  CAS  PubMed  Google Scholar 

  51. Bernecker C, Pailer S, Kieslinger P et al (2011) Increased matrix metalloproteinase activity is associated with migraine and migraine-related metabolic dysfunctions. Eur J Neurol 18:571–576

    Article  CAS  PubMed  Google Scholar 

  52. Martins-Oliveira A, Speciali JG, Dach F et al (2009) Different circulating metalloproteinases profiles in women with migraine with and without aura. Clin Chim Acta 408:60–64

    Article  CAS  PubMed  Google Scholar 

  53. Leira R, Sobrino T, Rodríguez-Yáñez M et al (2007) MMP-9 Immunoreactivity in Acute Migraine. Headache J Head Face Pain 47:698–702

    Article  Google Scholar 

  54. Imamura K, Takeshima T, Fusayasu E, Nakashima K (2007) Increased Plasma Matrix Metalloproteinase-9 Levels in Migraineurs. Headache J Head Face Pain 48:135–139

    Google Scholar 

  55. Ashina M, Tvedskov JF, Lipka K et al (2009) Matrix metalloproteinases during and outside of migraine attacks without aura. Cephalalgia 30(3):303–310

    Article  Google Scholar 

  56. Tsan MF (1985) Mechanism of gallium-67 accumulation in inflammatory lesions. J Nucl Med 26:88–92

    CAS  PubMed  Google Scholar 

  57. Karatas H, Erdener SE, Gursoy-Ozdemir Y et al (2011) Spreading Depression Triggers Headache by Activating Neuronal Panx1 Channels. J Acquir Immune Defic Syndr 17:621

    Google Scholar 

  58. Schain AJ, Melo-Carrillo A, Borsook D et al (2019) Activation of pial and dural macrophages and dendritic cells by CSD (67 chrs). Ann Neurol 83:508–521

    Article  CAS  Google Scholar 

  59. Schain AJ, Melo-Carrillo A, Ashina S et al (2020) Celecoxib reduces cortical spreading depression-induced macrophage activation and dilatation of dural but not pial arteries in rodents: implications for mechanism of action in terminating migraine attacks. Pain 161:1019–1026

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Viana M, Linde M, Sances G et al (2016) Migraine aura symptoms: Duration, succession and temporal relationship to headache. Cephalalgia 36:413–421

    Article  PubMed  Google Scholar 

  61. Takizawa T, Qin T, Lopes de Morais A et al (2020) Non-invasively triggered spreading depolarizations induce a rapid pro-inflammatory response in cerebral cortex. J Cereb Blood Flow Metab 40:1117–1131

    Article  CAS  PubMed  Google Scholar 

  62. Yücel M, Kotan D, Gurol ÇG et al (2016) Serum levels of endocan, claudin-5 and cytokines in migraine. Eur Rev Med Pharmacol Sci 20:930–936

    PubMed  Google Scholar 

  63. Zhang X, Burstein R, Levy D (2012) Local action of the proinflammatory cytokines IL-1β and IL-6 on intracranial meningeal nociceptors. Cephalalgia 32:66–72

    Article  CAS  PubMed  Google Scholar 

  64. Zhang X-C, Kainz V, Burstein R, Levy D (2011) Tumor necrosis factor-alpha induces sensitization of meningeal nociceptors mediated via local COX and p38 MAP kinase actions. Pain 152:140–149

    Article  CAS  PubMed  Google Scholar 

  65. Bowen EJ, Schmidt TW, Firm CS et al (2006) Tumor necrosis factor-α stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons. J Neurochem 96:65–77

    Article  CAS  PubMed  Google Scholar 

  66. Herisson F, Frodermann V, Courties G et al (2018) Direct vascular channels connect skull bone marrow and the brain surface enabling myeloid cell migration. Nat Neurosci 21:1209–1217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Grinberg YY, Dibbern ME, Levasseur VA, Kraig RP (2013) Insulin-Like Growth Factor-1 Abrogates Microglial Oxidative Stress and TNF-α Responses to Spreading Depression. J Neurochem 126:662–672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Jander S, Schroeter M, Peters O et al (2001) Cortical Spreading Depression Induces Proinflammatory Cytokine Gene Expression in the Rat Brain. J Cereb Blood Flow Metab 21:218

    Article  CAS  PubMed  Google Scholar 

  69. Cagnin A, Gerhard A, Banati RB (2002) In vivo imaging of neuroinflammation. Eur Neuropsychopharmacol 12:581–586

    Article  CAS  PubMed  Google Scholar 

  70. Sandiego CM, Gallezot JD, Pittman B et al (2015) Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc Natl Acad Sci 112:12468–12473

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Takizawa T, Shibata M, Kayama Y et al (2017) High-mobility group box 1 is an important mediator of microglial activation induced by cortical spreading depression. J Cereb Blood Flow Metab. https://doi.org/10.1177/0271678X16647398

  72. Schain AJ, Melo-Carrillo A, Stratton J et al (2019) CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP’s Role in Migraine with Aura. J Neurosci 39:6001–6011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Khan S, Amin FM, Christensen CE et al (2019) Meningeal contribution to migraine pain: A magnetic resonance angiography study. Brain 142:93–102

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark

    Rune Häckert Christensen, Cédric Gollion, Faisal Mohammad Amin & Messoud Ashina

  2. Department of Neurology, University Hospital of Toulouse, Toulouse, France

    Cédric Gollion

  3. Department of Neurorehabilitation/Traumatic Brain Injury, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

    Faisal Mohammad Amin

  4. Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA

    Michael A. Moskowitz & Nouchine Hadjikhani

  5. Gillberg Neuropsychiatry Center, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

    Nouchine Hadjikhani

Authors
  1. Rune Häckert Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cédric Gollion
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Faisal Mohammad Amin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael A. Moskowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nouchine Hadjikhani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Messoud Ashina
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

R.H.C. screened records, extracted data, wrote and edited the manuscript. C.G. screened records and extracted data. C.G., F.A., N.H., M.M, and M.A. critically revised the manuscript for intellectual content. M.A. conceptualized the manuscript. The authors read and approved the final manuscript.

Corresponding author

Correspondence to Messoud Ashina.

Ethics declarations

Competing interest

The authors declare that they have no competing interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Christensen, R.H., Gollion, C., Amin, F.M. et al. Imaging the inflammatory phenotype in migraine. J Headache Pain 23, 60 (2022). https://doi.org/10.1186/s10194-022-01430-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s10194-022-01430-y

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us